BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rozzo G, Ramondetta A, Fierro MT, Dapavo P, Ribero S. Moderate-to-severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak. Dermatol Ther 2020;33:e13680. [PMID: 32447800 DOI: 10.1111/dth.13680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Khan S, Karponis D, Wali G. Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid-19 pandemic: A UK dermatology tertiary centre experience. Skin Health Dis 2021;:e54. [PMID: 34235510 DOI: 10.1002/ski2.54] [Reference Citation Analysis]
2 Mintoff D, Chatterjee M, Podder I, Shipman A, Das A. Clinical Dermatology and COVID-19 Pandemic: Narrative Review. Indian J Dermatol 2021;66:246-55. [PMID: 34446947 DOI: 10.4103/ijd.ijd_463_21] [Reference Citation Analysis]
3 Rosi E, Fastame MT, Di Cesare A, Silvi G, Pimpinelli N, Prignano F. Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic. J Clin Med 2021;10:5841. [PMID: 34945136 DOI: 10.3390/jcm10245841] [Reference Citation Analysis]
4 Coskun Benlidayi I, Kurtaran B, Tirasci E, Guzel R. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. Rheumatol Int 2020;40:1707-16. [PMID: 32591970 DOI: 10.1007/s00296-020-04635-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
5 Jones ME, Kohn AH, Pourali SP, Rajkumar JR, Gutierrez Y, Yim RM, Armstrong AW. The Use of Biologics During the COVID-19 Pandemic. Dermatol Clin 2021;39:545-53. [PMID: 34556244 DOI: 10.1016/j.det.2021.05.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Patsatsi A, Kyriakou A. Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence? Clin Dermatol 2021;39:52-5. [PMID: 33972053 DOI: 10.1016/j.clindermatol.2020.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dewigne M, Orte Cano C, Daoud M, Del Marmol V, Benhadou F. Low incidence of COVID-19 in hidradenitis suppurativa: How to interpret it? Exp Dermatol 2021. [PMID: 34679208 DOI: 10.1111/exd.14475] [Reference Citation Analysis]